First Trust Advisors LP grew its stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 197.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,191 shares of the biotechnology company’s stock after buying an additional 89,724 shares during the period. First Trust […]
Repligen Co. (NASDAQ:RGEN – Get Rating) – Research analysts at SVB Leerink lowered their Q4 2023 earnings per share estimates for Repligen in a note issued to investors on Tuesday, May 2nd. SVB Leerink analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.63 for the quarter, down from […]
Repligen (NASDAQ:RGEN – Get Rating) had its price target lowered by research analysts at Deutsche Bank Aktiengesellschaft from $180.00 to $165.00 in a report issued on Wednesday, The Fly reports. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 4.94% from the company’s current price. RGEN has been the subject of several other reports. […]
Repligen (NASDAQ:RGEN – Get Rating) had its price target decreased by Craig Hallum from $220.00 to $207.00 in a report released on Wednesday, The Fly reports. Craig Hallum’s target price points to a potential upside of 31.65% from the stock’s current price. Several other research analysts have also recently commented on the company. SVB Leerink […]
Repligen Co. (NASDAQ:RGEN – Get Rating) – Stock analysts at William Blair reduced their Q3 2023 earnings estimates for Repligen in a research report issued on Wednesday, May 3rd. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $0.52 per share for the quarter, down from their prior forecast […]